Grisso has introduced a new precision probiotic line in the US, positioning the brand around clinically tested formulations.
According to the US-based microbial science company, it introduced three products built around its patented Weizmannia coagulans BC99 strain, which has been the subject of several clinical studies.
The first set of products includes G-Serein, formulated for sleep and stress support; G-Sylph, focused on women’s gut health; and G-Serene 4-In-1 Women’s Health Prebiotic + Probiotic, designed for vaginal health, urinary tract wellness and yeast balance.
Each supplement promises to offer 100 billion CFU (Colony-Forming Units, a standard microbiological metric used to estimate living bacterial or fungal cells in a sample) per serving.
Founder Pamela Garcia said the brand’s strategy is a response to what she called “the probiotic industry’s trust problem”.
Grisso has based its portfolio on a single extensively researched strain rather than multi-strain blends with limited individual evidence.
The business operates an integrated R&D and manufacturing facility in Ontario, California, giving it direct control over strain cultivation, development, testing and packaging.
According to the company, this vertical model supports proprietary research and faster formulation updates.
The launch takes place against a backdrop of rising demand for evidence-backed supplements, as well as growing emphasis on targeted, clinically supported probiotics from other premium players in the category, including Seed, Pendulum and Ritual.
Grisso is entering the market through a direct-to-consumer online model, accompanied by educational material on microbiome science and the clinical work underpinning its products.
The company describes itself as a microbial science business focused on clinically validated probiotic supplements, operating from its combined R&D and manufacturing base in Ontario, California.
Garcia added: “Consumers are overwhelmed by vague claims and products that don’t deliver. We’re focused on transparency—showing the research, controlling the manufacturing process, and targeting specific health outcomes rather than making broad wellness promises.”
